
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4882110/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Secondhand Smoke Exposure in European Countries With Different Smoke-Free Legislation: Findings From the EUREST-PLUS ITC Europe Surveys. Nicotine and Tobacco Research, 2022, 24, 85-92.	1.4	5
2	Trends and the course of liver cirrhosis and its complications in Germany: Nationwide population-based study (2005 to 2018). Lancet Regional Health - Europe, The, 2022, 12, 100240.	3.0	50
3	A longitudinal analysis of pneumococcal vaccine serotypes in pneumonia patients in Germany. European Respiratory Journal, 2022, 59, 2102432.	3.1	19
4	Early post-discharge mortality in CAP: frequency, risk factors and a prediction tool. European Journal of Clinical Microbiology and Infectious Diseases, 2022, 41, 621.	1.3	8
5	Pseudomonas aeruginosa Affects Airway Epithelial Response and Barrier Function During Rhinovirus Infection. Frontiers in Cellular and Infection Microbiology, 2022, 12, 846828.	1.8	5
6	Longitudinal Analysis of Coronavirus-Neutralizing Activity in COVID-19 Patients. Viruses, 2022, 14, 882.	1.5	3
7	Clinical predictors of survival in patients with relapsed/refractory small-cell lung cancer treated with checkpoint inhibitors: a German multicentric real-world analysis. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592210971.	1.4	9
8	Decision Conflicts in Clinical Care during COVID-19: A Patient Perspective. Healthcare (Switzerland), 2022, 10, 1019.	1.0	5
9	Chronic liver disease negatively affects outcome in hospitalised patients with community-acquired pneumonia. Gut, 2021, 70, 221-222.	6.1	7
10	Analysis of Humoral Immune Responses in Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection. Journal of Infectious Diseases, 2021, 223, 56-61.	1.9	65
11	The impact of the SARS-CoV-2 pandemic on the prevalence of respiratory tract pathogens in patients with community-acquired pneumonia in Germany. Emerging Microbes and Infections, 2021, 10, 1515-1518.	3.0	12
12	Pneumonia. Nature Reviews Disease Primers, 2021, 7, 25.	18.1	230
13	Technical Innovations in Pneumology: E-Health, Screening, Diagnostics, and Therapy. Respiration, 2021, 100, 1-7.	1.2	0
14	Pharyngeal spreading of peri-implant infections under antiresorptive/antiangiogenic therapy. International Journal of Implant Dentistry, 2021, 7, 43.	1.1	0
15	Interobserver agreement in interpretation of chest radiographs for pediatric community acquired pneumonia: Findings of the pedCAPNETZâ€cohort. Pediatric Pulmonology, 2021, 56, 2676-2685.	1.0	6
16	Implementation and use of mHealth home telemonitoring in adults with acute COVID-19 infection: a scoping review protocol. BMJ Open, 2021, 11, e053819.	0.8	7
17	Evaluation of a multiplex PCR screening approach to identify community-acquired bacterial co-infections in COVID-19: a multicenter prospective cohort study of the German competence network of community-acquired pneumonia (CAPNETZ). Infection, 2021, 49, 1299-1306.	2.3	8
18	Rate and Predictors of Bacteremia in Afebrile Community-Acquired Pneumonia. Chest, 2020, 157, 529-539.	0.4	20

#	Article	IF	CITATIONS
19	Pneumococcal conjugate serotype distribution and predominating role of serotype 3 in German adults with community-acquired pneumonia. Vaccine, 2020, 38, 1129-1136.	1.7	28
20	Transitions in product use during the implementation of the European Tobacco Products Directive: cohort study findings from the EUREST-PLUS ITC Europe Surveys. European Journal of Public Health, 2020, 30, iii10-iii17.	0.1	5
21	Changes in electronic cigarette use and label awareness among smokers before and after the European Tobacco Products Directive implementation in six European countries: findings from the EUREST-PLUS ITC Europe Surveys. European Journal of Public Health, 2020, 30, iii62-iii67.	0.1	3
22	Do-not-resuscitate orders in patients with community-acquired pneumonia: a retrospective study. BMC Pulmonary Medicine, 2020, 20, 201.	0.8	10
23	Predictors for longâ€ŧerm mortality in COPD patients requiring nonâ€invasive positive pressure ventilation for the treatment of acute respiratory failure. Clinical Respiratory Journal, 2020, 14, 1144-1152.	0.6	9
24	Aprotinin Inhibits SARS-CoV-2 Replication. Cells, 2020, 9, 2377.	1.8	72
25	Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19. JAMA - Journal of the American Medical Association, 2020, 324, 1317.	3.8	671
26	Evaluating the impact of the Tobacco Products Directive within the context of the FCTC in Europe—findings from the EUREST-PLUS ITC Europe Surveys: introductory Commentary. European Journal of Public Health, 2020, 30, iii1-iii3.	0.1	0
27	Awareness and use of heated tobacco products among adult smokers in six European countries: findings from the EUREST-PLUS ITC Europe Surveys. European Journal of Public Health, 2020, 30, iii78-iii83.	0.1	18
28	Awareness and correlates of noticing changes to cigarette packaging design after implementation of the European Tobacco Products Directive: findings from the EUREST-PLUS ITC Europe Surveys. European Journal of Public Health, 2020, 30, iii98-iii107.	0.1	4
29	Support for e-cigarette policies among smokers in seven European countries: longitudinal findings from the 2016–18 EUREST-PLUS ITC Europe Surveys. European Journal of Public Health, 2020, 30, iii68-iii77.	0.1	5
30	Social norms for e-cigarettes and smoking: associations with initiation of e-cigarette use, intentions to quit smoking and quit attempts: findings from the EUREST-PLUS ITC Europe Surveys. European Journal of Public Health, 2020, 30, iii46-iii54.	0.1	10
31	Impact of the Tobacco Products Directive on self-reported exposure to e-cigarette advertising, promotion and sponsorship in smokers—findings from the EUREST-PLUS ITC Europe Surveys. European Journal of Public Health, 2020, 30, iii55-iii61.	0.1	7
32	European Respiratory Society International Congress, Madrid, 2019: nontuberculous mycobacterial pulmonary disease highlights. ERJ Open Research, 2020, 6, 00317-2020.	1.1	9
33	A pathway to keep all lifelong learners up to date: the ERS continuing professional development programme. European Respiratory Journal, 2020, 55, 1902425.	3.1	2
34	Effectiveness of tobacco warning labels before and after implementation of the European Tobacco Products Directive—findings from the longitudinal EUREST-PLUS ITC Europe surveys. European Journal of Public Health, 2020, 30, iii84-iii90.	0.1	5
35	Cessation behaviours among smokers of menthol and flavoured cigarettes following the implementation of the EU Tobacco Products Directive: findings from the EUREST-PLUS ITC Europe Surveys. European Journal of Public Health, 2020, 30, iii34-iii37.	0.1	10
36	Learning in the workplace: Use of informal feedback cues in doctorâ€patient communication. Medical Education, 2020, 54, 811-820.	1.1	22

#	Article	IF	Citations
37	No SARS-CoV-2 detection in the German CAPNETZ cohort of community acquired pneumonia before COVID-19 peak in March 2020. Infection, 2020, 48, 971-974.	2.3	6
38	Perceptions of people with respiratory problems on physician performance evaluation—A qualitative study. Health Expectations, 2020, 23, 247-255.	1,1	6
39	Methods of the International Tobacco Control (ITC) EUREST-PLUS ITC Europe Surveys. European Journal of Public Health, 2020, 30, iii4-iii9.	0.1	21
40	The REMAP-CAP (Randomized Embedded Multifactorial Adaptive Platform for Community-acquired) Tj ETQq0 0 0	rgBT /Ove	erlock 10 Tf 5 245
41	Histologische Sicherung einer peripheren pulmonalen LĤon mittels ultraschlanken Bronchoskops und radiĤen endobronchialen Ultraschalls bei einem Patienten mit schwerem Lungenemphysem als Kontraindikation fļr chirurgische oder computertomographiegesteuerte Verfahren. , 2020, 74, .		0
42	Im Spannungsfeld zwischen Anspruch und Wirklichkeit: intravenĶse antibiotische Suppressionstherapien bei erwachsenen CF-Patienten an einem groÄŸen deutschen CF-Zentrum. Pneumologie, 2020, 74, .	0.1	0
43	Pseudomonas aeruginosa alters inflammatory response of primary bronchial epithelial cells to Rhinovirus infection in vitro. Pneumologie, 2020, 74, .	0.1	0
44	Hohe Letalitäbei schwerer respiratorischer Insuffizienz trotz extrakorporalem Lungenersatz (ECMO) bei Patienten mit zystischer Fibrose. Pneumologie, 2020, 74, .	0.1	0
45	Patient Science – Patienten schaffen Wissen. Eine bürgerwissenschaftliche Studie am Beispiel der Mukoviszidose. Pneumologie, 2020, , .	0.1	0
46	Vergleich der Surrogatmarker (BMI, FEV1, Notwendigkeit einer i. v. Antibiotikatherapie) von CF-Patienten mit und ohne Paeruginosa-Infektion in Frankfurt und Moskau zwischen 1990 und 2015. , 2020, 74, .		0
47	Impact of chronic liver disease on mortality and severity in community-acquired pneumonia (CAP) – Results from the German Competence Network CAPNETZ. Pneumologie, 2020, 74, .	0.1	0
48	The Glycemic Gap and 90-Day Mortality in Community-acquired Pneumonia. A Prospective Cohort Study. Annals of the American Thoracic Society, 2019, 16, 1518-1526.	1.5	12
49	Cell Type- and Exposure-Specific Modulation of CD63/CD81-Positive and Tissue Factor-Positive Extracellular Vesicle Release in response to Respiratory Toxicants. Oxidative Medicine and Cellular Longevity, 2019, 2019, 1-9.	1.9	16
50	Macrolide combination therapy for patients hospitalised with community-acquired pneumonia? An individualised approach supported by machine learning. European Respiratory Journal, 2019, 54, 1900824.	3.1	20
51	Serum levels of hyaluronic acid are associated with COPD severity and predict survival. European Respiratory Journal, 2019, 53, 1801183.	3.1	27
52	Risk stratification for shortâ€ŧerm mortality at hospital admission for acute exacerbations of COPD. Respirology, 2019, 24, 765-776.	1.3	16

53	Pulmonary nocardiosis in Western Europe—Clinical evaluation of 43 patients and population-based estimates of hospitalization rates. International Journal of Infectious Diseases, 2019, 81, 140-148.	1.5	39
54	Proteomic analysis reveals procoagulant properties of cigarette smoke-induced extracellular vesicles. Journal of Extracellular Vesicles, 2019, 8, 1585163.	5.5	33

4

#	Article	IF	CITATIONS
55	Is chronic obstructive pulmonary disease a risk factor for death in patients with community acquired pneumonia?. Infectious Diseases, 2019, 51, 340-347.	1.4	15
56	Meeting challenges in delivery of patient care: a reflection on the involvement of ERS in CPD of respiratory physicians. Breathe, 2019, 15, e97-e103.	0.6	0
57	PedCAPNETZ – prospective observational study on community acquired pneumonia in children and adolescents. BMC Pulmonary Medicine, 2019, 19, 238.	0.8	4
58	A Case of Lymphangioleiomyomatosis (LAM) of the Lung in a Patient with a History of Breast Cancer. American Journal of Case Reports, 2019, 20, 390-393.	0.3	3
59	Late Breaking Abstract - An ethnographic study on respiratory physicians' communicative repertoire. , 2019, , .		0
60	Associations between biomarkers at discharge and co-morbidities and risk of readmission after community-acquired pneumonia: a retrospective cohort study. European Journal of Clinical Microbiology and Infectious Diseases, 2018, 37, 1103-1111.	1.3	12
61	IFN $\hat{\mathbf{b}}$ 3/4 locus polymorphisms and IFN $\hat{\mathbf{b}}$ 3 circulating levels are associated with COPD severity and outcomes. BMC Pulmonary Medicine, 2018, 18, 51.	0.8	12
62	Extracellular vesicles released in response to respiratory exposures: implications for chronic disease. Journal of Toxicology and Environmental Health - Part B: Critical Reviews, 2018, 21, 142-160.	2.9	49
63	Redox-dependent thiol modifications: implications for the release of extracellular vesicles. Cellular and Molecular Life Sciences, 2018, 75, 2321-2337.	2.4	68
64	Update of the ERS international Adult Respiratory Medicine syllabus for postgraduate training. Breathe, 2018, 14, 19-28.	0.6	7
65	Treatment with long acting muscarinic antagonists stimulates serum levels of irisin in patients with COPD. Pulmonary Pharmacology and Therapeutics, 2018, 48, 111-116.	1.1	4
66	ERS syllabus for postgraduate training in respiratory infections: a guide for comprehensive training. Breathe, 2018, 14, 269-275.	0.6	1
67	Doctors on the move: a European case study on the key characteristics of national recertification systems. BMJ Open, 2018, 8, e019963.	0.8	19
68	ERS Congress highlight: educational forum on continuing professional development. Breathe, 2018, 14, e12-e16.	0.6	2
69	Increased Small Intestinal Permeability during Severe Acute Exacerbations of COPD. Respiration, 2018, 95, 334-342.	1.2	44
70	Collagen Degradation and Formation Are Elevated in Exacerbated COPD Compared With Stable Disease. Chest, 2018, 154, 798-807.	0.4	42
71	Box-ticking and Olympic high jumping – Physicians' perceptions and acceptance of national physician validation systems. Medical Teacher, 2018, 40, 886-891.	1.0	12
72	Serum hyaluronidase-1 is increased in COPD exacerbations and is associated with COPD severity and outcomes. , 2018, , .		1

#	Article	IF	CITATIONS
73	Cross-border purchasing of cigarettes among smokers in Six Countries of the EUREST-PLUS ITC Europe Surveys. Tobacco Induced Diseases, 2018, 16, A13.	0.3	8
74	The purchase sources of and price paid for cigarettes in six European countries: Findings from the EUREST-PLUS ITC Europe Surveys. Tobacco Induced Diseases, 2018, 16, A16.	0.3	6
75	Receiving support to quit smoking and quit attempts among smokers with and without smoking related diseases: Findings from the EUREST-PLUS ITC Europe Surveys. Tobacco Induced Diseases, 2018, 16, A14.	0.3	11
76	Social norms towards smoking and electronic cigarettes among adult smokers in seven European Countries: Findings from the EUREST-PLUS ITC Europe Surveys. Tobacco Induced Diseases, 2018, 16, A15.	0.3	13
77	Study protocol of EUREST-PLUS - European Regulatory Science on Tobacco: Policy Implementation to Reduce Lung Disease. Tobacco Induced Diseases, 2018, 16, A2.	0.3	39
78	Extent and correlates of self-reported exposure to tobacco advertising, promotion and sponsorship in smokers: Findings from the EUREST-PLUS ITC Europe Surveys. Tobacco Induced Diseases, 2018, 16, .	0.3	8
79	Impact of anti-smoking advertising on health-risk knowledge and quit attempts across 6 European countries from the EUREST-PLUS ITC Europe Survey. Tobacco Induced Diseases, 2018, 16, A5.	0.3	7
80	Characterising smokers of menthol and flavoured cigarettes, their attitudes towards tobacco regulation, and the anticipated impact of the Tobacco Products Directive on their smoking and quitting behaviours: The EUREST-PLUS ITC Europe Surveys. Tobacco Induced Diseases, 2018, 16, A4.	0.3	27
81	Quitting activity and use of cessation assistance reported by smokers in eight European countries: Findings from the EUREST-PLUS ITC Europe Surveys. Tobacco Induced Diseases, 2018, 16, .	0.3	31
82	Patterns of tobacco use, quit attempts, readiness to quit and selfefficacy among smokers with anxiety or depression: Findings among six countries of the EUREST-PLUS ITC Europe Surveys. Tobacco Induced Diseases, 2018, 16, A9.	0.3	11
83	Cigarette brand loyalty among smokers in six European countries: Findings from the EUREST-PLUS ITC Europe Surveys. Tobacco Induced Diseases, 2018, 16, A12.	0.3	9
84	Secondhand exposure to e-cigarette aerosols among smokers: A cross-sectional study in six European countries of the EUREST-PLUS ITC Europe Surveys. Tobacco Induced Diseases, 2018, 16, A11.	0.3	10
85	Knowledge of the health risks of smoking and impact of cigarette warning labels among tobacco users in six European countries: Findings from the EUREST-PLUS ITC Europe Surveys. Tobacco Induced Diseases, 2018, 16, A10.	0.3	20
86	The Conceptual Model and Methods of Wave 1 (2016) of the EUREST-PLUS ITC 6 European Countries Survey. Tobacco Induced Diseases, 2018, 16, A3.	0.3	35
87	Extracellular matrix glycosaminoglycans can predict severity and outcome in COPD. , 2018, , .		Ο
88	Prevalence and correlates of different smoking bans in homes and cars among smokers in 6 Countries of the EUREST-PLUS ITC Europe Surveys. Tobacco Induced Diseases, 2018, 16, A8.	0.3	8
89	Impact of exacerbations on adherence and outcomes of pulmonary rehabilitation in patients with <scp>COPD</scp> . Respirology, 2017, 22, 942-949.	1.3	12
90	Failure of CRP decline within three days of hospitalization is associated with poor prognosis of Community-acquired Pneumonia. Infectious Diseases, 2017, 49, 251-260.	1.4	23

#	Article	IF	CITATIONS
91	Continuing professional development: introducing the ERS International Certificate in Respiratory Sleep Medicine. Breathe, 2017, 13, 11-14.	0.6	5
92	Cigarette smoke extract induced exosome release is mediated by depletion of exofacial thiols and can be inhibited by thiol-antioxidants. Free Radical Biology and Medicine, 2017, 108, 334-344.	1.3	62
93	European Respiratory Society guidelines for the management of adult bronchiectasis. European Respiratory Journal, 2017, 50, 1700629.	3.1	788
94	Introducing an updated international ERS syllabus for postgraduate training 2017. Breathe, 2017, 13, e53-e55.	0.6	3
95	Re-certification of respiratory professionals: current practice and the future – educational forum report. Breathe, 2017, 13, 77-80.	0.6	Ο
96	Taken to task: what is and is not an appropriate response to an ERS guidelines task force?. European Respiratory Journal, 2017, 50, 1700952.	3.1	1
97	Ultrafiltration combined with size exclusion chromatography efficiently isolates extracellular vesicles from cell culture media for compositional and functional studies. Scientific Reports, 2017, 7, 15297.	1.6	193
98	Penicillin treatment for patients with Community-Acquired Pneumonia in Denmark: a retrospective cohort study. BMC Pulmonary Medicine, 2017, 17, 66.	0.8	30
99	The impact of blood glucose on community-acquired pneumonia: a retrospective cohort study. ERJ Open Research, 2017, 3, 00114-2016.	1.1	19
100	Systemic Biomarkers of Collagen and Elastin Turnover Are Associated With Clinically Relevant Outcomes in COPD. Chest, 2017, 151, 47-59.	0.4	59
101	Undiagnosed Diabetes Mellitus in Community-Acquired Pneumonia: A Prospective Cohort Study. Clinical Infectious Diseases, 2017, 65, 2091-2098.	2.9	26
102	Risk of community-acquired pneumonia in chronic obstructive pulmonary disease stratified by smoking status: a population-based cohort study in the United Kingdom. International Journal of COPD, 2017, Volume 12, 2425-2432.	0.9	19
103	Undiagnosed diabetes mellitus in community-acquired pneumonia - A prospective cohort study. , 2017, , ·		4
104	Basal membrane biomarkers in stable and exacerbated COPD. , 2017, , .		0
105	IFNL3 polymorphisms are associated with COPD severity and outcomes. , 2017, , .		Ο
106	Association between biomarkers at discharge and risk of readmission after community-acquired pneumonia $\hat{a} \in $ a retrospective cohort study. , 2017, , .		0
107	Response to non-invasive ventilation as a predictor for mortality in patients with acute respiratory failure due to acute exacerbation of COPD. , 2017, , .		1
108	Hyaluronic acid, heparan sulfate and chondroitin sulfate are altered during exacerbations of COPD. , 2017, , .		0

#	Article	IF	CITATIONS
109	Irisin is associated with clinical outcomes and up-regulated by long-acting anticholinergics in COPD. , 2017, , .		0
110	CAB score predicts short-term mortality at hospital admission for acute exacerbations of COPD. , 2017, , .		0
111	The glycemic gap and 90-day mortality in community-acquired pneumonia- A prospective cohort study. , 2017, , .		0
112	Do not resuscitat orders in community-acquired pneumonia: a restrospective cohort study. , 2017, , .		0
113	Advances in the prevention, management, and treatment of community-acquired pneumonia. F1000Research, 2016, 5, 300.	0.8	26
114	Therapy with protonâ€pump inhibitors for gastroesophageal reflux disease does not reduce the risk for severe exacerbations in COPD. Respirology, 2016, 21, 883-890.	1.3	32
115	HERMES European Accreditation of Training Centres in Adult Respiratory Medicine: criteria validation and revision. Breathe, 2016, 12, 11-17.	0.6	3
116	Severity Assessment and the Immediate and Long-Term Prognosis in Community-Acquired Pneumonia. Seminars in Respiratory and Critical Care Medicine, 2016, 37, 886-896.	0.8	20
117	Exposure to common respiratory bacteria alters the airway epithelial response to subsequent viral infection. Respiratory Research, 2016, 17, 68.	1.4	50
118	<i>Stenotrophomonas maltophilia</i> ventilator-associated pneumonia. A retrospective matched case-control study. Infectious Diseases, 2016, 48, 738-743.	1.4	14
119	Prognostic assessment in COPD without lung function: the B-AE-D indices. European Respiratory Journal, 2016, 47, 1635-1644.	3.1	37
120	Impact of pneumococcal vaccination in children on serotype distribution in adult community-acquired pneumonia using the serotype-specific multiplex urinary antigen detection assay. Vaccine, 2016, 34, 2342-2348.	1.7	31
121	Alteration of canonical and non-canonical WNT-signaling by crystalline silica in human lung epithelial cells. Toxicology and Applied Pharmacology, 2016, 301, 61-70.	1.3	19
122	The ever-expanding ERS fellowship programmes: achievements over the past 3 years. European Respiratory Journal, 2016, 48, 595-599.	3.1	1
123	Endobronchial ultrasound: launch of an ERS structured training programme. Breathe, 2016, 12, 217-220.	0.6	41
124	Burden of COPD in patients treated in different care settings in the Netherlands. Respiratory Medicine, 2016, 118, 76-83.	1.3	20
125	Comparison of the qSOFA and CRB-65 for risk prediction in patients with community-acquired pneumonia. Intensive Care Medicine, 2016, 42, 2108-2110.	3.9	43
126	Introducing a new HERMES project on respiratory infections. Breathe, 2016, 12, 5-7.	0.6	6

#	Article	IF	CITATIONS
127	The European Respiratory Society evaluates its 2013–2018 strategic plan implementation. European Respiratory Journal, 2016, 47, 693-698.	3.1	3
128	Community-acquired Haemophilus influenzae pneumonia – New insights from the CAPNETZ study. Journal of Infection, 2016, 72, 554-563.	1.7	21
129	The EMBARC European Bronchiectasis Registry: protocol for an international observational study. ERJ Open Research, 2016, 2, 00081-2015.	1.1	133
130	3-day mortality in hospitalised community-acquired pneumonia: frequency and risk factors. European Respiratory Journal, 2016, 47, 1572-1574.	3.1	12
131	Viral–bacterial interactions in the respiratory tract. Journal of General Virology, 2016, 97, 3089-3102.	1.3	50
132	Performance of early warning score and CURB-65 in predicting severe outcome in community-acquired pneumonia. , 2016, , .		1
133	The impact of hyperglycemia on community-acquired pneumonia: A retrospective cohort study. , 2016, , .		0
134	Risk of CAP in COPD stratified by smoking status: A population-based cohort study in the UK. , 2016, , .		0
135	The impact of exacerbations on adherence and outcomes of pulmonary rehabilitation in patients with COPD. , 2016, , .		0
136	Hyaluronic acid as a novel systemic biomarker to predict progression and severity in chronic obstructive pulmonary disease. , 2016, , .		1
137	Empiric penicillin monotherapy of CAP is not associated with increased mortality; experiences from the retrospective CAP-North cohort. , 2016, , .		0
138	ERS/EBAP European Accreditation of Training Centres in Adult Respiratory Medicine: how could it benefit your centre?. Breathe, 2015, 11, 183-185.	0.6	3
139	Mannose-binding lectin protein and its association to clinical outcomes in COPD: a longitudinal study. Respiratory Research, 2015, 16, 150.	1.4	18
140	Feasibility, safety, clinical, and laboratory effects of convalescent plasma therapy for patients with Middle East respiratory syndrome coronavirus infection: a study protocol. SpringerPlus, 2015, 4, 709.	1.2	163
141	Risk factors for mortality in patients with pulmonary infections with non-tuberculous mycobacteria: A retrospective cohort study. Respiratory Medicine, 2015, 109, 137-145.	1.3	38
142	Assessment of oxygenation and comorbidities improves outcome prediction in patients with communityâ€acquired pneumonia with a low CRBâ€65 score. Journal of Internal Medicine, 2015, 278, 193-202.	2.7	43
143	Randomized double blind placebo-controlled study to demonstrate that antibiotics are not needed in moderate acute exacerbations of COPD – The ABACOPD Study. BMC Pulmonary Medicine, 2015, 15, 5.	0.8	16
144	Community-acquired pneumonia as medical emergency: predictors of early deterioration. Thorax, 2015, 70, 551-558.	2.7	73

#	Article	IF	CITATIONS
145	<i>Mycoplasma pneumoniae</i> and <i>Chlamydia</i> spp. Infection in Community-Acquired Pneumonia, Germany, 2011–2012. Emerging Infectious Diseases, 2015, 21, 426-434.	2.0	99
146	LATE-BREAKING ABSTRACT: Biomarkers of ECM turnover and clinical relevant outcomes in COPD: Results of the multicenter PROMISE study. , 2015, , .		1
147	Cigarette smoke extract induces the release of extracellular vesicles by airway epithelial cells via cellular carbonyl stress. , 2015, , .		1
148	Use of Dipeptidyl-Peptidase-4 Inhibitors and the Risk of Pneumonia: A Population-Based Cohort Study. PLoS ONE, 2015, 10, e0139367.	1.1	21
149	Prognostic assessment in chronic obstructive pulmonary disease using copeptin: A simplified risk index. , 2015, , .		0
150	Mannose binding lectin - <i>HYPD</i> allele is associated with frequent exacerbation in COPD patients. , 2015, , .		0
151	Hyaluronic acid is associated with survival time in stable COPD independently of exacerbation rate, BODE index and adjusted Charlson score. , 2015, , .		Ο
152	LSC Abstract – Synergistic pro-inflammatory effects of Haemophilus influenzae/RSV co-infections on respiratory epithelial cells. , 2015, , .		0
153	Characterization of patients with COPD GOLD stage I and II referred for pulmonary rehabilitation. , 2015, , .		Ο
154	Irisin is associated with severe exacerbations of COPD independently of lung function, comorbidities and exercise capacity. , 2015, , .		0
155	Efficacy of IFN-λ1 to Protect Human Airway Epithelial Cells against Human Rhinovirus 1B Infection. PLoS ONE, 2014, 9, e95134.	1.1	16
156	Adrenomedullin refines mortality prediction by the BODE index in COPD: the "BODE-A" index. European Respiratory Journal, 2014, 43, 397-408.	3.1	41
157	CXC chemokines and antimicrobial peptides in rhinovirusâ€induced experimental asthma exacerbations. Clinical and Experimental Allergy, 2014, 44, 930-939.	1.4	47
158	Defining a training framework for clinicians in respiratory critical care. European Respiratory Journal, 2014, 44, 572-577.	3.1	5
159	"Education is the passport to the future": enabling today's medical teachers to prepare tomorrow's respiratory health practitioners. European Respiratory Journal, 2014, 44, 578-584.	3.1	9
160	Vitamin D deficiency in community-acquired pneumonia: low levels of 1,25(OH)2 D are associated with disease severity. Respiratory Research, 2014, 15, 53.	1.4	58
161	Open source clinical science for emerging infections. Lancet Infectious Diseases, The, 2014, 14, 8-9.	4.6	82
162	The host immune response contributes toÂHaemophilus influenzae virulence. Respiratory Medicine, 2014, 108, 144-152.	1.3	6

#	Article	IF	CITATIONS
163	Detection of respiratory viruses using a multiplex real-time PCR assay in Germany, 2009/10. Archives of Virology, 2014, 159, 669-676.	0.9	31
164	Dysnatremia, vasopressin, atrial natriuretic peptide and mortality in patients with community-acquired pneumonia. Respiratory Medicine, 2014, 108, 1696-1705.	1.3	42
165	The relevance of respiratory viral infections in the exacerbations of chronic obstructive pulmonary disease—A systematic review. Journal of Clinical Virology, 2014, 61, 181-188.	1.6	89
166	Antibiotics for community-acquired pneumonia in adult outpatients. The Cochrane Library, 2014, 2014, CD002109.	1.5	56
167	Similar matrix alterations in alveolar and small airway walls of COPD patients. BMC Pulmonary Medicine, 2014, 14, 90.	0.8	49
168	Exertional Hypoxemia in Stable COPD Is Common and Predicted by Circulating Proadrenomedullin. Chest, 2014, 146, 328-338.	0.4	20
169	Increased Severity and Mortality of CAP in COPD: Results from the German Competence Network, CAPNETZ. Chronic Obstructive Pulmonary Diseases (Miami, Fla), 2014, 2, 131-140.	0.5	11
170	The role of viruses in CAP. , 2014, , 74-87.		5
171	Interferon-β induces a long-lasting antiviral state in human respiratory epithelial cells. Journal of Infection, 2013, 66, 163-169.	1.7	24
172	Predictors of 1-Year Mortality at Hospital Admission for Acute Exacerbations of Chronic Obstructive Pulmonary Disease. Respiration, 2013, 85, 15-26.	1.2	70
173	Adult Patients With Nosocomial Pneumonia. Deutsches Ärzteblatt International, 2013, 110, 634-40.	0.6	26
174	Frequent Detection of Latent Tuberculosis Infection among Aged Underground Hard Coal Miners in the Absence of Recent Tuberculosis Exposure. PLoS ONE, 2013, 8, e82005.	1.1	9
175	The role of viruses in chronic bronchitis and exacerbations of COPD. , 2013, , 68-75.		0
176	Nursing-home-acquired pneumonia in Germany: an 8-year prospective multicentre study. Thorax, 2012, 67, 132-138.	2.7	103
177	Serum glucose levels for predicting death in patients admitted to hospital for community acquired pneumonia: prospective cohort study. BMJ, The, 2012, 344, e3397-e3397.	3.0	113
178	The Burden of Pneumococcal Pneumonia - Experience of the German Competence Network CAPNETZ. Pneumologie, 2012, 66, 470-475.	0.1	77
179	Levels of Soluble Triggering Receptor Expressed on Myeloid Cells 1 in Infectious Exacerbations of Chronic Obstructive Pulmonary Disease. Respiration, 2012, 83, 133-139.	1.2	14
180	Community-acquired pneumonia in younger patients is an entity on its own. European Respiratory Journal, 2012, 39, 1156-1161.	3.1	53

#	Article	IF	CITATIONS
181	The remaining challenges of pneumococcal disease in adults. European Respiratory Review, 2012, 21, 57-65.	3.0	79
182	Serum cortisol predicts death and critical disease independently of CRB-65 score in community-acquired pneumonia: a prospective observational cohort study. BMC Infectious Diseases, 2012, 12, 90.	1.3	44
183	Presentation, etiology and outcome of pneumonia in younger nursing home residents. Journal of Infection, 2012, 65, 32-38.	1.7	14
184	More than classical Chlamydia psittaci in urban pigeons. Veterinary Microbiology, 2012, 157, 476-480.	0.8	79
185	Viruses and bacteria in acute asthma exacerbations – A GA ² LENâ€ÐARE* systematic review. Allergy: European Journal of Allergy and Clinical Immunology, 2011, 66, 458-468.	2.7	237
186	Healthcare workers and influenza vaccination: an ERS-ESCMID Web-based survey. Clinical Microbiology and Infection, 2011, 17, 1223-1225.	2.8	16
187	Within-Subject Variability of Mycobacterium tuberculosis-Specific Gamma Interferon Responses in German Health Care Workers. Vaccine Journal, 2011, 18, 1176-1182.	3.2	65
188	Rhinovirus vaccination: the case in favour. European Respiratory Journal, 2011, 37, 3-4.	3.1	13
189	Viral colonization in intubated patients: initial pathogen pattern and followâ€up. Clinical Respiratory Journal, 2010, 4, 139-146.	0.6	1
190	Predictors of persistently positive Mycobacterium-tuberculosis-specific interferon-gamma responses in the serial testing of health care workers. BMC Infectious Diseases, 2010, 10, 220.	1.3	73
191	Chlamydial Zoonoses. Deutsches Ärzteblatt International, 2010, 107, 174-80.	0.6	51
192	Upper respiratory tract infections. , 2010, , 3227-3231.		1
193	Frequency and clinical relevance of human bocavirus infection in acute exacerbations of chronic obstructive pulmonary disease. International Journal of COPD, 2009, 4, 111.	0.9	16
194	A fatal case of spinal tuberculosis mistaken for metastatic lung cancer: recalling ancient Pott's disease. Annals of Clinical Microbiology and Antimicrobials, 2009, 8, 32.	1.7	27
195	In-hospital contact investigation among health care workers after exposure to smear-negative tuberculosis. Journal of Occupational Medicine and Toxicology, 2009, 4, 11.	0.9	28
196	Respiratory virus induction of alphaâ€; beta―and lambdaâ€interferons in bronchial epithelial cells and peripheral blood mononuclear cells. Allergy: European Journal of Allergy and Clinical Immunology, 2009, 64, 375-386.	2.7	192
197	No evidence for WU polyomavirus infection in chronic obstructive pulmonary disease. Infectious Agents and Cancer, 2009, 4, 12.	1.2	3
198	Drug Targets in Rhinoviral Infections. Infectious Disorders - Drug Targets, 2009, 9, 126-132.	0.4	17

#	Article	IF	CITATIONS
199	Inflammatory Response in Acute Viral Exacerbations of COPD. Infection, 2008, 36, 427-433.	2.3	53
200	Therapeutic Targets in Respiratory Viral Infections. Current Medicinal Chemistry, 2007, 14, 2776-2782.	1.2	9
201	Synergistically Upregulated Interleukin-10 Production in Cocultures of Monocytes and T Cells after Stimulation with Respiratory Syncytial Virus. International Archives of Allergy and Immunology, 2007, 142, 116-126.	0.9	11
202	Mechanisms of virus-induced asthma exacerbations: state-of-the-art. A GA2LEN and InterAirways document. Allergy: European Journal of Allergy and Clinical Immunology, 2007, 62, 457-470.	2.7	84
203	Association of the ASP299GLY TLR4 polymorphism with COPD. Respiratory Medicine, 2006, 100, 892-896.	1.3	33
204	Impaired virus-induced interferon-alpha2 release in adult asthmatic patients. Clinical and Experimental Allergy, 2006, 36, 331-337.	1.4	92
205	Association of interleukin-8 receptor $\hat{I}\pm$ polymorphisms with chronic obstructive pulmonary disease and asthma. Genes and Immunity, 2005, 6, 225-230.	2.2	42
206	Polymorphisms in theinterleukin-8 gene in patients with chronic obstructive pulmonary disease. Electrophoresis, 2005, 26, 2888-2891.	1.3	19
207	Evaluation of the toll-like receptor 6 Ser249Pro polymorphism in patients with asthma, atopic dermatitis and chronic obstructive pulmonary disease. BMC Medical Genetics, 2005, 6, 34.	2.1	54
208	Soluble Interleukin-5 Receptor Alpha Is Increased in Acute Exacerbation of Chronic Obstructive Pulmonary Disease. International Archives of Allergy and Immunology, 2004, 135, 54-61.	0.9	20
209	A promotor polymorphism in theInterleukin 11 gene is associated with chronic obstructive pulmonary disease. Electrophoresis, 2004, 25, 804-808.	1.3	24
210	Increased IgE-antibodies to Staphylococcus aureus enterotoxins in patients with COPD. Respiratory Medicine, 2004, 98, 858-864.	1.3	40
211	Evaluation of a quantitative real-time PCR for the detection of respiratory syncytial virus in pulmonary diseases. European Respiratory Journal, 2003, 21, 944-951.	3.1	101
212	Respiratory viruses in exacerbations of chronic obstructive pulmonary disease requiring hospitalisation: a case-control study. Thorax, 2003, 58, 37-42.	2.7	454
213	Antibiotics in acute exacerbation of asthma and COPD. , 0, , 150-158.		0